Skip to Main Content

Hello, everyone, and how are you today? We are doing just fine, thank you. Clouds may be hovering over the Pharmalot campus, but our spirits remain sunny. After all, who can forget what the Morning Mayor would say – “Every brand new day should be unwrapped like a precious gift.” Sage advice is always welcome here. So while you tug on the ribbon, we will brew another cup of needed stimulation — we are back to cinnamon coffee roll — and get on with things. And so, here are some fresh tidbits. Have a great day …

Shire raised prices on two drugs by 9.2 percent so far this year, according to Jefferies analyst David Steinberg. As of July 18, the list price for Firazyr, which treats hereditary angioedema, rose 6 percent, while Gattex, used to treat short bowel syndrome, rose 5.9 percent. However, he noted the price hikes were on top of earlier increases. The higher list prices are just below double digits, a range some drug makers are targeting in hopes of avoiding criticism, but well above inflation.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!